

Fever-Related Arrhythmic Events in the Multicenter Survey on Arrhythmic Events in Brugada Syndrome (SABRUS)

Brief title: Brugada Syndrome and Fever-related Arrhythmias

Yoav Michowitz MD¹, Anat Milman MD PhD¹, Georgia Sarquella-Brugada MD PhD², Antoine Andorin MD³, Jean Champagne MD⁴, Pieter G. Postema MD PhD⁵, Ruben Casado-Arroyo MD PhD⁶, Eran Leshem MD^{1,7}, Jimmy JM Juang MD PhD⁸, Carla Giustetto MD⁹, Jacob Tfelt-Hansen MD DMSc¹⁰, Yanushi D. Wijeyeratne MD¹¹, Christian Veltmann MD¹², Domenico Corrado MD PhD¹³, Sung-Hwan Kim MD¹⁴, Pietro Delise MD¹⁵, Shingo Maeda MD PhD¹⁶, Jean-Baptiste Gourraud MD PhD³, Frederic Sacher MD¹⁷, Philippe Mabo MD¹⁸, Yoshihide Takahashi MD PhD¹⁶, Tsukasa Kamakura MD PhD¹⁸, Takeshi Aiba MD PhD¹⁸, Giulio Conte MD PhD²⁰, Aviram Hochstadt MD²¹, Yuka Mizusawa MD⁵, Michael Rahkovich MD^{1,22}, Elena Arbelo MD PhD²³, Zhengrong Huang MD PhD²⁴, Isabelle Denjoy MD²⁵, Carlo Napolitano MD PhD²⁶, Ramon Brugada MD PhD²⁷, Leonardo Calo MD²⁸, Silvia G. Priori MD PhD²⁶, Masahiko Takagi MD PhD²⁹, Elijah R. Behr MD¹¹, Fiorenzo Gaita MD⁹, Gan-Xin Yan MD PhD³⁰, Josep Brugada MD PhD²³, Antoine Leenhardt MD²⁵, Arthur A.M. Wilde MD PhD⁵, Pedro Brugada MD PhD²⁰, Kengo F. Kusano MD PhD¹⁸, Kenzo Hirao MD PhD¹⁶, Gi-Byoung Nam MD PhD³¹, Vincent Probst MD PhD³, Bernard Belhassen MD¹

Word count: 4610

- (1) Department of Cardiology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- (2) Pediatric Arrhythmias, Electrophysiology and Sudden Death Unit Cardiology, Department Hospital Sant Joan de Déu, Barcelona - Universitat de Barcelona, Spain.
- (3) L'institut du Thorax, Service de Cardiologie, CHU de Nantes, Nantes, France.
- (4) Quebec Heart and Lung Institute, Quebec City, Canada.
- (5) Heart Centre AMC, Department of Clinical and Experimental Cardiology, AMC, University of Amsterdam, Amsterdam Netherlands.
- (6) Department of Cardiology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- (7) Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- (8) Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
- (9) Division of Cardiology, University of Torino, Department of Medical Sciences, Città della Salute e della Scienza Hospital, Torino, Italy.
- (10) The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, and Department of Medicine and Surgery, University of Copenhagen, Copenhagen, Denmark.

- (11) Cardiovascular Sciences, St. George's University of London and Cardiology Clinical Academic Group St. George's University Hospitals NHS Foundation Trust, London, UK.
- (12) Rhythmology and Electrophysiology, Department of Cardiology, Hannover Medical School, Hannover, Germany.
- (13) Department of Cardiac, Thoracic and Vascular Sciences University of Padova, Padova, Italy.
- (14) Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- (15) Division of Cardiology, Hospital of Peschiera del Garda, Veneto, Italy.
- (16) Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
- (17) Hôpital Cardiologique du Haut-Lévêque & Université Bordeaux, LIRYC Institute.), Bordeaux, France.
- (18) Cardiology and Vascular Disease Division, Rennes University Health Centre, Rennes, France.
- (19) Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan.
- (20) Heart Rhythm Management Centre, UZ-VUB, Brussels, Belgium.
- (21) Department of Internal Medicine J, Tel-Aviv Medical Center, Tel Aviv, Israel.
- (22) Arrhythmia Services, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- (23) Cardiology Department, Cardiovascular Institute, Hospital Clinic and IDIBAPS, Barcelona, Catalonia, Spain.
- (24) Department of Cardiology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
- (25) Service de Cardiologie et CNMR Maladies Cardiaques Hérititaires Rares, Hôpital Bichat, Paris, and Université Paris Diderot, Sorbonne, Paris, France.
- (26) Molecular Cardiology, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
- (27) Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona-IdIBGi, Spain.
- (28) Division of Cardiology, Policlinico Casilino, Roma, Italy.
- (29) Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan.
- (30) Lankenau Medical Center, Wynnewood, Pennsylvania, USA.
- (31) Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funding: None.

Disclosures: None

Address for correspondence:

Bernard Belhassen, MD
 Department of Cardiology
 Tel-Aviv Sourasky Medical Center
 Weizman St 6, Tel-Aviv, 64239, Israel
 E-mail: bblhass@gmail.com
 Phone: 972.3.697.4762
 Fax: 972.3.697.4418

Acknowledgements: We thank Dr. Tomer Ziv-Baran for statistical analysis support.

Abstract

Aims: The literature on fever related arrhythmic events (AE) in Brugada syndrome (BrS) patients is currently limited to few case reports and small series.

The current study aims to describe the characteristics of fever-related AE in a large cohort of BrS patients.

Methods and Results: SABRUS is a multicenter study that gathered data from 678 BrS patients with first AE documented at time of aborted cardiac arrest (CA) (n=426) or after prophylactic ICD implantation (n=252). In 35(6%) of the 588 patients with available information, the AE occurred during a febrile illness.

Most of the 35 patients were male (80%), Caucasian (83%) and proband (70%). Age at time of AE was 29 ± 24 (range 0.3-76) years. Most patients (80%) presented with aborted CA and 6 (17%) with arrhythmic storm. Family history of sudden death, history of syncope and spontaneous type 1 Brugada-ECG were noted in 17%, 40% and 66% of patients, respectively. VF was induced at EPS in 9/19(47%) patients. An *SCN5A* mutation was found in 14/28(50%) patients. The highest proportion of fever-related AE was observed in the pediatric population (age <16), especially the very young (0-5 years old) (67%). Males were involved in all age groups and females only in the pediatric and elderly groups. Fever-related AE affected 17 Caucasians aged <24 years, but no Asians aged <24 years.

Conclusions: The risk of fever-related AE in BrS markedly varies according to age group, gender and ethnicity. Taking these factors into account could help the clinical management of BrS patients with fever.

Key words: Fever, Brugada syndrome, children, elderly, gender, ethnicity

Brugada syndrome (BrS) is an inherited disease that predisposes to sudden cardiac death (SCD), striking mainly males aged 27-59 years old¹. Risk factors for malignant ventricular arrhythmias during follow-up include: a previous history of aborted SCD or malignant syncope, and inducible ventricular fibrillation (VF) at electrophysiological study (EPS)^{2,3}, spontaneous type 1 Brugada-ECG⁴, ECG markers of QRS fragmentation^{5,6} and prominent S wave in lead I⁷. In addition, several factors are known to precipitate an arrhythmic event (AE) in BrS patients such as specific drugs⁸, increase in vagal tone⁹ and fever¹⁰.

The *SCN5A*-encoded α -subunit of the NaV1.5 cardiac sodium channel has been linked to BrS and mutations in *SCN5A* are identified in 14–26% of BrS cases¹¹. Dumaine et al.¹² were the first to link temperature with the function of a mutant *SCN5A* sodium channel. Later it was demonstrated that fever may induce type 1 ECG in BrS patients¹³. Two large studies demonstrated that in unselected populations with fever, type 1 Brugada-ECG may be seen in 2-4% of patients^{14,15} but none of these patients experienced malignant AE's. However, Mizusawa and colleagues¹⁶ recently demonstrated that, as opposed to patients who have only drug challenge induced type 1 ECG, those with fever-induced type 1 ECG (F-type 1) have an increased risk for symptomatic disease including syncope and VF. Likewise, there are only few case reports and small series describing patients with BrS and proven fever-related AE. The Survey on Arrhythmic events in BRUGada Syndrome (SABRUS) is a multicenter study that collected data on the first AE in 678 patients with BrS¹. The objective of the present study was to describe the characteristics of patients with fever-related AE in this large SABRUS patient cohort.

Methods

The study was approved by the Tel Aviv Medical Center Institutional Review Board committee.

The 678 SABRUS patients originated from 23 centers in 10 Western and 4 Asian countries¹.

Sixteen (69.5%) centers provided data from their institution only, whereas the remaining 7 (31.5%) provided data from multiple institutions from their countries.

Data acquisition. Study inclusion criteria consisted of 1) a typical type 1 Brugada-ECG either spontaneously or following the intravenous administration of a cardiac sodium channel blocking drug; 2) a first documented AE (sustained ventricular tachyarrhythmia). Anonymous patient information was collected using a predefined questionnaire regarding the following: 1) whether or not the AE was associated with fever; 2) age at the time of the first AE; 3) mode of AE documentation (group A or group B, see below); 4) gender; 5) proband status; 6) ethnicity (Caucasian, Asian, other or unknown); 7) family history of SCD; 8) prior history of syncope ; 9) presence of spontaneous or drug-induced type 1 Brugada-ECG; 10) inducibility of VF at EPS and 11) presence of *SCN5A* mutation.

Definitions. The patients were classified in 2 groups according to the mode of AE documentation:

- Group A: Patients with documented aborted CA in whom the BrS-diagnosis was made during work-up performed after CA.
- Group B: Patients with a BrS-diagnosis in whom prophylactic ICD implantation was performed for any reason and in whom an AE requiring appropriate ICD therapy was documented during follow-up by ICD interrogation.

Proband status: Proband was defined as the first patient of a family who has been diagnosed with the type-1 Brugada-ECG (spontaneous or drug-induced). A non-proband was defined as a family member of a known BrS-patient.

Age groups: For analyzing the effect of age on fever-related AE, patients were divided into 8 age categories: 1) early childhood: 0-5 years; 2) late childhood: 6-15 years; 3) adult life: 16-70 years, divided in 5 equal bins of 11 years; 4) elderly: age >70 years old.

Model for predicting the risk of AE per day of fever. In order to predict the risk of AE per day of fever (day at risk) in each age group a model which took in account the data provided by all 23 main centers participating in SABRUS was built. These centers were invited to participate in a registry by providing the age and gender distribution of the entire BrS population followed at their own center (with or without prior AE). The centers from Western and Asian countries were assumed to include Caucasian and Asian patients, respectively, based on SABRUS results showing that only 1.7% of the patients from Western countries had an Asian origin while no patient from Asian countries was Caucasian¹.

The Delphi method ¹⁷ was used in order to estimate the average number of fever days per year in the 8-different age groups. Briefly, 10 physicians (5 experts in adult internal medicine and 5 experts in pediatrics) were contacted separately by e-mail. They were asked to give an estimation of the average fever days in each age group in a step wise approach; first, they were blinded of the estimations given by other participants. Before the second and third tours the average of the 10 answers given for each age group was sent to the participants and they were allowed to change their answer accordingly.

As the exact birth date of the patients was unknown the model assumed the AE occurred at the middle of the year (after 6 months) and therefore the days at risk (or days with fever) for patients with an AE were assumed to be half of the estimation provided by the Delphi method

The event per day at risk was calculated as =
$$\frac{\text{The number of events per the specific age group}}{\text{Days at risk}}$$

While *days at risk* for the specific age group =

*= No. of patients without AE * fever days per year + No. of patients with AE * fever days per six month.*

The 95% CI for the “event per day at risk” was calculated using the WINPEPI computer program¹⁸.

Statistical analysis.

Assumptions of normality of the different ages were assessed by Kolmogorov–Smirnov test and Q-Q plots. Differences between non-normally distributed ages were assessed using a Mann–Whitney U test. Ratio differences were examined by a Chi-square test or a Fisher's exact test as appropriate. Statistical significance was defined as $P < 0.05$. Scale variables are presented as Median [IQR] for when not normally distributed. All calculations were performed using SPSS version 24 (IBM, Armonk, NY, USA).

Results

Study patient cohort.

SABRUS gathered 678 BrS patients with first AE, including 588 (86.7%) patients in whom there was information available on a possible relationship between AE and fever. In 35 (5.95%) of these 588 patients, the AE occurred during a febrile illness. These 35 patients comprised the study group.

Characteristics of patients with fever-related AE.

The characteristics of the 35 patients with AE associated with fever are presented in Table 1. Of note, the vast majority ($n=32$) of these patients provided from the main SABRUS centers while only 3 provided from subsidiary medical centers.

Most patients were male (28 of 35, 80%) and Caucasian (29 of 35, 83%) with a mean age of 29 ± 24 (range 0.3-76) years at the time of AE. The vast majority (28 of 35, 80%) presented with aborted CA (group A) while the remaining patients belonged to group B. Six (17%) patients

presented with VF storm. Most patients were probands (70%). A family history of SCD and a history of syncope were noted in 17% and 40% of patients, respectively. A spontaneous type 1 Brugada-ECG was observed in 24 (66%) of patients. VF was induced at EPS in 9 (47%) of the 19 patients who underwent the procedure. An *SCN5A* mutation was found in 14 (50%) of the 28 patients who underwent genetic testing.

Comparison between patients with or without fever-related AE.

The age distribution was markedly different in the 2 patient groups (Fig. 1A). In the study group, 13 (37.1%) of the 35 AE occurred in the pediatric population (age ≤ 16 years) especially in the very young (≤ 5 years) (11 of 13, 84.6%); the AE occurred between ages 16-70 in 20 (57.1%) patients and after age 70 in 2 (5.7%) patients (Fig. 1A). In contrast, in the patients with AE not related to fever, the AE mainly occurred (96%) between 16-70 years and rarely in the pediatric and elderly age groups (2.9% and 1.1%), respectively ($P < 0.001$) (Fig. 1A). When analyzing the percentage of patients with fever-related AE in regard to the total number of patients with AE in SABRUS, the highest AE rate was observed during early childhood (age 0-5, 65%), followed by a marked decline during late childhood (age 6-15, 16.7%) and adulthood (age 16-70, 3.6%) with a subsequent marked rise to 25% in the elderly (Fig. 1A).

Comparisons between patients with and without fever-related AE are presented in Table 2.

Patients with fever-related AE had a lower proportion of males (80% vs. 92%, $P=0.03$) and probands (70% vs. 87%, $P=0.02$). In contrast, they were more likely to be younger at time of AE [median age (IQR) of 25 (3-46) vs. 43 (34-52), $P<0.001$], to belong to Group A (80% vs. 59%, $P=0.02$), to be Caucasian (83% vs. 56%, $P=0.007$) and to be *SCN5A* mutation carriers (50% vs. 31%, $P=0.04$).

Other variables including family history of SCD, history of syncope, positive EPS, spontaneous type 1 Brugada-ECG and presentation with an arrhythmic storm were not significantly different among the 2 groups.

Comparison between males and females with fever-related AE.

Comparisons between males and females with fever-related AE are presented in Table 3A.

Females with fever-related AE were younger [(median age (IQR) of 3 (0.4-16) vs. 35.5 (7.25-46.75), $P=0.04$]. The age distribution of males and females and the percentage of fever-related AE at different age groups are presented in Figure 1B. As shown, all fever-related AE in females were censored from early childhood until age of 16 with no other cases during adulthood except for a single 70-year old female. In contrast fever-related AE in males occurred in all age groups. The rate of fever-related AE tended to be higher in female patients aged <26 years as compared to males in the same age group (43% vs. 16.7%, $P=0.065$). Another difference between males and females concerned the EPS response. An inducible arrhythmia was observed in 64% of tested males but in none of the females ($P=0.03$). Other analyzed variables were not gender specific.

Comparison between children (age <16) and adults (age ≥ 16) with fever-related AE.

This comparison is presented in Table 3B. There was a tendency toward a higher percentage of females (38% vs. 9%, $P=0.08$) and Caucasians (100% vs. 73%, $P=0.06$) among children with fever-related AE as compared to adults. An *SCN5A* mutation was significantly more frequently observed in children (77% vs. 27% in adults, $P=0.008$). Other variables including mode of AE presentation, proband status, family history of SCD, history of syncope, spontaneous type 1 Brugada-ECG, inducible arrhythmia at EPS and VF storm were not different between children and adults.

Comparison between Caucasians and Asians with fever-related AE.

This comparison is presented in Table 3C. Caucasians tended to be younger than Asians [median age (IQR) of 22 (3-45) vs. 42 (31-61), $P=0.05$]. Among the patients with fever-related AE, there were 17 Caucasians aged ≤ 24 years old including 11 patients aged ≤ 5 years whereas the younger Asian patient was 25 years old. Caucasians tended to exhibit a spontaneous type 1 Brugada-ECG ($P=0.06$). The other variables tested were not significantly different in respect to patient ethnicity.

Estimation of arrhythmic risk for 1000 fever days.

Twenty-two of the 23 main SABRUS centers provided the age and gender distribution of the entire BrS population followed at their own center (with or without prior AE). The registry comprised 6441 patients (73.4% males, 88% Caucasians) including 500 patients with and 5941 without AE. Of note, the other 178 SABRUS patients who were not followed by the main participating centers and in whom the denominator from which these patients were collected was unknown, were not included in the present sub-analysis. In 77 of the 500 SABRUS patients, there was no information available about the possible association of fever with AE and therefore these 77 patients were also excluded from further analysis. A flowchart describing patient selection is presented in Figure 2. As shown, overall 32 patients had and 6332 patients did not have fever-related AE.

The age-group distribution of the patients with and without fever-related AE is presented in table 4, demonstrating that 70.9% of the BrS population were 27-59 years old. This table also denotes the estimated yearly fever days from the Delphi method. As shown, the estimated average fever days per year of children aged 0-5 was 2.6-3.7 times higher compared to age categories ranging from 16-70 years old and 1.7-1.8 times higher compared to age groups 6-15 and >70. Figure 3

demonstrates the estimated AE rate per 1000 fever days according to the specific age group. It shows an estimated rate of 14.8 AE (95% CI 7.4, 26.3) per 1000 fever days in BrS patients aged 0-5 years old with similar rates between females and males. In contrast, the estimated AE rate dropped to 0.33-2.5 events per 1000 fever days in all other age groups.

Discussion

Main findings.

The present study describes the largest series ever reported of BrS patients with fever-related AE. It shows that $\approx 6\%$ of AE in BrS were associated with fever. These AE mainly occurred in Caucasians males, in all age groups and often with a presentation of aborted CA. The highest proportion of fever-related AE was observed in the pediatric population (age <16), especially the very young (0-5 years old). Marked gender differences were noted with involvement of males in all age groups contrasting with exclusive female involvement in the pediatric and elderly groups. Fever-related AE did not involve any Asian patient aged <25 years old. Also, the youngest patient group (age 0-5) exhibited the highest estimated rate of AE per 1000 fever days in the BrS population, with similar rates between males and females.

Prior reports on fever-related AE.

Table 5 summarizes all previous publications of fever-related AE in BrS comprising 40 patients in 22 reports. Only 4 (18%) of the 22 reports included patients (n=9) who originated from Asian countries. Careful analysis of these publications, as well as contact with the respective authors, enabled us to confirm that up to 15 cases included in SABRUS had been already published, however with very limited data that did not include age and gender in most of them^{10, 19, 20}. The largest report includes 7 patients¹⁹ while 16 (72%) of these 22 publications dealt with case reports. Age and gender were provided for 18 (45%) and 23 (57%) patients, respectively. Male

involvement was observed in all age groups; however, there were 8 females with fever induced AE at very young age (≤ 2 years, $n=6$) or after menopause (≥ 50 years, $n=2$). ECG data was provided on 18 patients (45%) showing spontaneous type 1 Brugada-ECG in 8 (44%). Thirteen out of 19 tested patients (68%) had *SCN5A* mutations. EPS was performed in 4 patients and was positive in all of them.

Brugada and fever.

Two studies examined the prevalence of fever induced Brugada pattern (F-type 1) among febrile patients referred to the emergency department. Adler et al.¹⁴ reported a prevalence of 2%, while Rattanawong et al.¹⁵ who conducted their study in an endemic area found a higher 4% prevalence. The latter, which is 20 times more than the known prevalence of BrS in the general population^{21, 22}, suggests that fever induced Brugada-ECG changes are benign. Indeed, none of the patients in these 2 studies developed an AE during follow up. However, Mizusawa et al.¹⁶ found that among 88 asymptomatic patients at baseline who developed F-type 1 Brugada-ECG, 3 (3.4%) developed an AE including 1 which was fever-related. The AE event rate in these 88 asymptomatic patients was 0.9%/year i.e. similar to the event rate in patients with spontaneous type 1 (0.5-0.8% /year) and higher than the event rate in patients with drug-induced type 1 ECG (0-0.35%/year)¹⁶. Thus, Mizusawa et al.¹⁶ suggested that the occurrence of F-type 1 is probably a sign of poorer prognosis, yet it by no means implies that the risk for AE is present only or mainly during fever.

Gender and fever-related AE.

In the total SABRUS population of 678 patients with AE, females accounted for 8.7% of the cohort¹. In the present study, however, females involved 20% of the population which exhibited fever-related AE.

One possible explanation for this apparent higher propensity of females to develop fever-related AE deals with the higher SCN5A mutation rate observed in patients with fever-related AE (50% vs. 31% in those without fever-related) (Table 2), especially in females (80% vs. 43% in males) (Table 3A). In this scenario, one could hypothesize on a more proarrhythmic effect of fever in mutation carriers.

Another interesting finding of our study was the exclusive occurrence of AE in females at childhood or the elderly while this occurred at all age groups in males. This was also observed by others (see Table 5) and suggests an “antiarrhythmic protection” in females during their reproductive period. Several theories were raised regarding the protective role of female gender on disease manifestation including: gender differences in ionic currents²³ and the effect of sex hormones²⁴. Thus, one may speculate that estrogen and not the absence of testosterone is the main protector against fever-related AE in females during their reproductive period.

Children and fever-related AE.

Children (age <16 years) represented a considerable proportion of patients with fever-related AE (37.1%) despite they comprised only 4.3% the total SABRUS population¹. We found that children of both genders exhibited a considerable risk of fever-related AE as compared with patients in all other age groups. AE were related with fever in 67% and 16.7% of patients aged 0-5 and 6-15, respectively, while this was the case in only 3.9% of those patients aged ≥ 16 years. Previous studies^{25, 26} suggested a higher risk of fever-related symptoms in children; however most described episodes of syncope and not a proven AE^{26, 27}. As children have more febrile illnesses compared to adults it was speculated that a greater risk exposure may lead to this high rate of fever-related symptoms²⁶. However, when taking into account both total BrS population and the average yearly fever days in each age group we found that the risk of AE in a

comparable risk exposure (i.e. 1000 fever days) is much higher only among *children aged 0-5 years* compared to any other group. On the other hand, the higher event rate in children aged 6-15 may be related to more fever days with similar event rate per 1000 fever days as adults. The exact mechanism of this cluster of event in ages 0-5 is unknown and should be further investigated. Nevertheless, it has clinical implications as discussed below.

Another interesting finding of the present study was the higher rate of *SCN5A* mutation in children with fever-induced AE (77%) as compared to adults (27%) ($P=0.02$). The significance of this very high mutation rate should be interpreted with caution since our study was not powered to determine whether BrS children *without SCN5A* mutation have lower risk of AE during fever. Nevertheless, significantly lower mutation rates (59 of 201, 29.3%, $P=0.001$) were found in children without previous documented AE aged <16 years (Andorin and Probst, Sarquella-Brugada, Giustetto and Conte, personal communication, 2017). Therefore, it is possible that the presence of *SCN5A* mutation in children may indicate a higher arrhythmic risk during fever.

Elderly and fever-related AE.

AE's in the elderly population (>70 years) with BrS are rare, accounting for 1% of cases of AE in 678 SABRUS patients. The paucity of AE in the elderly was also reported by others²⁸⁻³⁰.

However, we found a 25% rate of fever-related AE in the 70+ age group. Yet, when taking into account the total BrS population and fever days, which are estimated to be higher than in adults (age<70), the estimated risk of AE per 1000 fever days was not significantly different from other age groups except from early childhood. Thus, it seems that the risk of AE in the elderly is similar to adults. Larger studies in the elderly group are needed to confirm our findings.

Ethnicity and fever-related AE.

There were 2 main differences between Caucasians and Asians with regard to fever-related AE. First, Caucasians predominated much more in the fever-related AE group than in the afebrile-related AE group. Secondly, Asians with fever-related AE were much older and the youngest in our cohort was 25 years old. A review of the literature (Table 5) confirms the extreme rarity of the involvement of Asians in fever-related AE, especially in children, with a single report of rapid monomorphic VT in a 2.2 year-old Korean child³¹. The lower risk for fever-related AE in Asian children may suggest that their mutation is sensitive to testosterone, which absence during childhood may also protect from the effect of fever. Further research is needed to explore this possibility.

Clinical implications.

Our results demonstrate that fever-related AE is the first manifestation of the disease in the majority of patients and may occur in a substantial number of previously asymptomatic patients without spontaneous type 1 Brugada-ECG. Therefore, in accordance with the current guidelines³², aggressive antipyretic therapy should be administered to any BrS patient with fever. In addition, special attention should be provided to those children (especially those aged 0-5 years) with syncope and/or febrile seizures who should undergo ECG to exclude the possibility of transient BrS-related AE³³. A survey conducted among pediatric electrophysiologists found that only 3% of them recommend admission for observation of BrS children with fever³⁴. Our findings suggest that a policy of lower threshold for in-hospital observation should be adopted in children, especially in Caucasians aged ≤ 5 years. However, based on our present study and prior reports, the risk of AE of any type (fever-related or not) in Asian children seems to be extremely low allowing to recommend a more liberal hospitalization policy. Moreover, our data suggest that the presence of *SCN5A* mutation in children may indicate a higher arrhythmic risk during

fever. Finally, BrS females at their reproductive age also have a very low AE risk and can be managed conservatively with antipyretics at outpatient settings, unless any alarming symptoms occur.

Limitations.

Not all SABRUS patients were followed by the participating centers and the denominator from which these patients were collected was unknown. Yet, even if these 178 patients had been excluded the results demonstrated in Tables 2-3 would not change meaningfully (Supplemental tables 1-2), thus minimizing the possibility of a bias. The study is retrospective and details regarding whether the patients had type 1 Brugada-ECG changes during fever (F-type 1) were not available, precluding the analysis of F-type ECG changes as a risk factor for AE. Our model of AE event risk per 1000 fever days is based on a calculated estimation of 10 experts since we do not know the exact risk exposure (fever days) of our BrS population. Finally, the number of females and elderly patients is limited and larger cohorts of these subgroups are needed.

Conclusions

Around 6% of AE in BrS patients are associated with fever. The risk of fever-related AE in BrS markedly varies according to age group, gender and ethnical origin of patients. Taking these factors into account may help in the clinical management of BrS patients with fever.

References

1. Milman A, Andorin A, Gourraud JB, Sacher F, Mabo P, Kim SH, Maeda S, Takahashi, Kamakura T, Aiba T, Conte G, Juang JM, Leshem E, Rahkovich M, Hochstadt A, Mizusawa Y, Postema PG, Arbelo E, Huang Z, Denjoy I, Giustetto C, Wijeyeratne YD, Napolitano C, Michowitz Y, Brugada R, Casado-Arroyo R, Champagne J, Calo L, Sarquella-Brugada G, Tfelt-Hansen J, Priori SG, Takagi M, Veltmann C, Delise P, Corrado D, Behr ER, Gaita F, Yan GX, Brugada J, Leenhardt A, Wilde AA, Brugada P, Kusano KF, Hirao K, Nam GB, Probst V, Belhassen B. Age of first arrhythmic event in Brugada syndrome: Data from the survey on arrhythmic events in Brugada syndrome (SABRUS) in 678 patients. *Circ Arrhythm Electrophysiol.* 2017. In Press.
2. Sieira J, Conte G, Ciconte G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, Di Giovanni G, Saitoh Y, Julia J, Mugnai G, La Meir M, Wellens F, Czapla J, Pappaert G, de Asmundis C and Brugada P. A score model to predict risk of events in patients with Brugada syndrome. *Eur Heart J.* 2017;38:1756-1763.
3. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, Zorzi A, Champagne J, Kostopoulou A, Yin X, Napolitano C, Milan DJ, Wilde A, Sacher F, Borggrefe M, Ellinor PT, Theodorakis G, Nault I, Corrado D, Watanabe I, Antzelevitch C, Allocca G, Priori SG and Lubitz SA. Programmed ventricular stimulation for risk stratification in the Brugada syndrome: A pooled analysis. *Circulation.* 2016;133:622-30.
4. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, Babuty D, Sacher F, Giustetto C, Schulze-Bahr E, Borggrefe M, Haissaguerre M, Mabo P, Le Marec H, Wolpert C and Wilde AA. Long-term prognosis of patients diagnosed with Brugada syndrome: Results from the FINGER Brugada syndrome registry. *Circulation.* 2010;121:635-43.
5. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, Giordano U, Pappone C, Mascioli G, Rossetti G, De Nardis R and Colombo M. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. *J Am Coll Cardiol.* 2012;59:37-45.
6. Morita H, Kusano KF, Miura D, Nagase S, Nakamura K, Morita ST, Ohe T, Zipes DP and Wu J. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. *Circulation.* 2008;118:1697-704.
7. Calo L, Giustetto C, Martino A, Sciarra L, Cerrato N, Marziali M, Rauzino J, Carlino G, de Ruvo E, Guerra F, Rebecchi M, Lanzillo C, Anselmino M, Castro A, Turreni F, Penco M, Volpe M, Capucci A and Gaita F. A new electrocardiographic marker of sudden death in Brugada syndrome: The S-wave in lead I. *J Am Coll Cardiol.* 2016;67:1427-40.
8. Konigstein M, Rosso R, Topaz G, Postema PG, Friedensohn L, Heller K, Zeltser D, Belhassen B, Adler A and Viskin S. Drug-induced Brugada syndrome: Clinical characteristics and risk factors. *Heart Rhythm.* 2016;13:1083-7.
9. Ikeda T, Abe A, Yusu S, Nakamura K, Ishiguro H, Mera H, Yotsukura M and Yoshino H. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. *J Cardiovasc Electrophysiol.* 2006;17:602-7.
10. Amin AS, Meregalli PG, Bardai A, Wilde AA and Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. *Ann Intern Med.* 2008;149:216-8.
11. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, Yamagishi M, Makita N, Sakurada H, Tanaka T, Shimizu A, Hagiwara N, Kishi R, Nakano Y, Takagi M, Makiyama T, Ohno S, Fukuda K, Watanabe H, Morita H, Hayashi K, Kusano K, Kamakura S, Yasuda S, Ogawa H, Miyamoto Y, Kapplinger JD, Ackerman MJ and Shimizu W. Genotype-phenotype correlation of SCN5A mutation for the clinical and electrocardiographic characteristics of probands with Brugada syndrome: A Japanese multicenter registry. *Circulation.* 2017;135:2255-2270.

12. Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, Brugada R and Antzelevitch C. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. *Circ Res.* 1999;85:803-9.
13. Porres JM, Brugada J, Urbistondo V, Garcia F, Reviejo K and Marco P. Fever unmasking the Brugada syndrome. *Pacing Clin Electrophysiol.* 2002;25:1646-8.
14. Adler A, Topaz G, Heller K, Zeltser D, Ohayon T, Rozovski U, Halkin A, Rosso R, Ben-Shachar S, Antzelevitch C and Viskin S. Fever-induced Brugada pattern: how common is it and what does it mean? *Heart Rhythm.* 2013;10:1375-82.
15. Rattanawong P, Vutthikraivit W, Charoensri A, Jongraksak T, Prombandankul A, Kanjanahattakij N, Rungaramsin S, Wisaratapong T and Ngarmukos T. Fever-induced Brugada syndrome is more common than previously suspected: A cross-sectional study from an endemic area. *Ann Noninvasive Electrocardiol.* 2016;21:136-41.
16. Mizusawa Y, Morita H, Adler A, Havakuk O, Thollet A, Maury P, Wang DW, Hong K, Gandjbakhch E, Sacher F, Hu D, Amin AS, Lahrouchi N, Tan HL, Antzelevitch C, Probst V, Viskin S and Wilde AA. Prognostic significance of fever-induced Brugada syndrome. *Heart Rhythm.* 2016;13:1515-20.
17. Boulkedid R, Abdoul H, Loustau M, Sibony O and Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. *PLoS One.* 2011;6:e20476.
18. Abramson JH. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. *Epidemiol Perspect Innov.* 2011;8:1.
19. Junttila MJ, Gonzalez M, Lizotte E, Benito B, Vernooy K, Sarkozy A, Huikuri HV, Brugada P, Brugada J and Brugada R. Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. *Circulation.* 2008;117:1890-3.
20. Andorin A, Behr ER, Denjoy I, Crotti L, Dagradi F, Jesel L, Sacher F, Petit B, Mabo P, Maltret A, Wong LC, Degand B, Bertaux G, Maury P, Dulac Y, Delasalle B, Gourraud JB, Babuty D, Blom NA, Schwartz PJ, Wilde AA and Probst V. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. *Heart Rhythm.* 2016;13:1274-82.
21. Antzelevitch C, Brugada P, Borggreffe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H and Wilde A. Brugada syndrome: report of the second consensus conference. *Heart Rhythm.* 2005;2:429-40.
22. Mizusawa Y and Wilde AA. Brugada syndrome. *Circ Arrhythm Electrophysiol.* 2012;5:606-16.
23. Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, Scornik FS and Antzelevitch C. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. *Circulation.* 2002;106:2004-11.
24. James AF, Choisy SC and Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. *Prog Biophys Mol Biol.* 2007;94:265-319.
25. Conte G, Dewals W, Sieira J, de Asmundis C, Ciconte G, Chierchia GB, Di Giovanni G, Baltogiannis G, Saitoh Y, Levinstein M, La Meir M, Wellens F, Pappaert G and Brugada P. Drug-induced brugada syndrome in children: clinical features, device-based management, and long-term follow-up. *J Am Coll Cardiol.* 2014;63:2272-9.
26. Probst V, Denjoy I, Meregalli PG, Amirault JC, Sacher F, Mansourati J, Babuty D, Villain E, Victor J, Schott JJ, Lupoglazoff JM, Mabo P, Veltmann C, Jesel L, Chevalier P, Clur SA, Haissaguerre M, Wolpert C, Le Marec H and Wilde AA. Clinical aspects and prognosis of Brugada syndrome in children. *Circulation.* 2007;115:2042-8.
27. Zaidi AN. An unusual case of Brugada syndrome in a 10-year-old child with fevers. *Congenit Heart Dis.* 2010;5:594-8.
28. Conte G, C DEA, Sieira J, Levinstein M, Chierchia GB, G DIG, Baltogiannis G, Ciconte G, Saitoh Y, Casado-Arroyo R, Pappaert G and Brugada P. Clinical characteristics, management, and prognosis of elderly patients with Brugada syndrome. *J Cardiovasc Electrophysiol.* 2014;25:514-9.

29. Kamakura T, Wada M, Nakajima I, Ishibashi K, Miyamoto K, Okamura H, Noda T, Aiba T, Takaki H, Yasuda S, Ogawa H, Shimizu W, Makiyama T, Kimura T, Kamakura S and Kusano K. Evaluation of the necessity for cardioverter-defibrillator implantation in elderly patients with Brugada syndrome. *Circ Arrhythm Electrophysiol.* 2015;8:785-91.
30. Kitamura T FS, Kawamura I, Hojo R, Aoyama Y, Nishizaki M, Hiraoka M, Sakurada H. Clinical characteristics and long-term prognosis of senior patients with Brugada syndrome. *J Am Coll Cardiol EP.* 2017;3:57-67.
31. Kim G, Kyung YC, Kang IS, Song J, Huh J and On YK. A pediatric case of Brugada syndrome diagnosed by fever-provoked ventricular tachycardia. *Korean J Pediatr.* 2014;57:374-8.
32. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G and Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. *Heart Rhythm.* 2013;10:1932-63.
33. Skinner JR, Chung SK, Nel CA, Shelling AN, Crawford JR, McKenzie N, Pinnock R, French JK and Rees MI. Brugada syndrome masquerading as febrile seizures. *Pediatrics.* 2007;119:e1206-11.
34. Harris BU, Miyake CY, Motonaga KS and Dubin AM. Diagnosis and management of pediatric brugada syndrome: a survey of pediatric electrophysiologists. *Pacing Clin Electrophysiol.* 2014;37:638-42.

Figure legends

Figure 1A: Patient age distribution. Patients with (left panel) or without (middle panel) fever-related AE are shown. The percentage of patients with fever-related AE in each age group is presented on the right panel. The highest percentage of fever-related AE is observed during childhood (0-15 years) with another rise in percentage in the elderly (age >70)

Figure 1B: Age distribution in males and females. Patients with (left panel) or without (middle panel) fever-related AE are shown. The percentage of patients in each gender with fever-related AE in each age group is presented on the right panel. Since the only females in age groups 16-26 and 60-70 were 16 and 70 years old, respectively, there are no cases of females with fever-related AE between ages 17-69.

Figure 2: Flowchart. Flowchart describing total BrS patient population and how patients were divided into subgroups with and without fever-related AE (see text).

Figure 3: Estimated arrhythmic event rate per 1000 fever days in each age group. The circles represent the estimated rate and the whiskers represent the 95% CI. The estimated risk in children aged 0-5 is higher than any other group in both genders. When looking at the estimated event rate of all patients (marked in black), there is no overlap of any estimation including its 95% CI with that of 0-5 years old age group.